



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



C17 Sphingomyelin (d18:1/17:0)

Item No. 25592

CAS Registry No.: 121999-64-2
Formal Name: (7S)-4-hydroxy-7-[(1R,2E)-1-hydroxy-2-hexadecen-1-yl]-N,N,N-trimethyl-9-oxo-3,5-dioxo-8-aza-4-phosphapentacosan-1-aminium, 4-oxide, inner salt
Synonyms: Heptadecanoyl Sphingomyelin, N-Heptadecanoyl-D-erythro-Sphingosylphosphorylcholine, SM(d18:1/17:0), Sphingomyelin (d18:1/17:0)
MF: C₄₀H₈₁N₂O₆P
FW: 717.1
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

C17 Sphingomyelin (d18:1/17:0) is supplied as a solid. A stock solution may be made by dissolving the C17 sphingomyelin (d18:1/17:0) in the solvent of choice, which should be purged with an inert gas. C17 Sphingomyelin (d18:1/17:0) is soluble in organic solvents such as chloroform and methanol, which should be purged with an inert gas.

Description

C17 Sphingomyelin is a synthetic derivative of sphingomyelin (Item Nos. 22674 | 24345) that has been used as an internal standard for the quantification of sphingomyelin.^{1,2}

References

1. Yang, Y., Kuwano, T., Lagor, W.R., *et al.* Lipidomic analyses of female mice lacking hepatic lipase and endothelial lipase indicate selective modulation of plasma lipid species. *Lipids* **49(6)**, 505-515 (2014).
2. Ståhlman, M., Fagerberg, B., Adiels, M., *et al.* Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: Impact on small HDL particles. *Biochim Biophys. Acta.* **1831(11)**, 1609-1617 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/27/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM